[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lophora\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100571635","phase-1-study-to-evaluate-lph-5-in-healthy-subjects-100571635",false,"NCT06722820","Study to Evaluate LPH-5 in Healthy Subjects","Phase I, First-in-man, Randomised, Placebo-controlled, Single Dose Escalation Study to Investigate the Effects of LPH-5 on Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters in Healthy Participants","Inclusion Criteria:\n\n* Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, and clinical laboratory evaluations.\n\nExclusion Criteria:\n\n* Any condition or disease detected during the medical interview\u002Fphysical examination that could relapse during or immediately after the study, or would render the participant unsuitable for the study, place the participant at undue risk, or interfere with the ability of the participant to complete the clinical study, as determined by the Investigator.\n* Have a history of and\u002For current clinically significant determined by the Investigator\n* Consumes cannabis or cannabis-derived compounds more than 3 times per month or has substantial changes in cannabis consumption in the 21 days prior to screening.",true,"MALE","18 Years","65 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.",[28,29],"Safety Issues","Tolerance","NOT_YET_RECRUITING","2024-12-03",{"date":33,"type":34},"2024-12-09","ACTUAL",{"date":36,"type":22},"2025-04-30",{"date":38,"type":22},"2025-12-31",{"name":40,"class":41},"Lophora","INDUSTRY",""]